ID   BT-549-Dox
AC   CVCL_UJ22
DR   cancercelllines; CVCL_UJ22
DR   Wikidata; Q93432704
RX   PubMed=7902062;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; HGNC:2092; CLTC + HGNC; HGNC:29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line).
CC   Misspelling: HTB-122-Dox; Note=Based on the ATCC catalog number of the parent cell line.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1092 ! BT-549
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 12
//
RX   PubMed=7902062;
RA   de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T.,
RA   Mannervik B., Bergh J.;
RT   "Characterization of four doxorubicin adapted human breast cancer cell
RT   lines with respect to chemotherapeutic drug sensitivity, drug
RT   resistance associated membrane proteins and glutathione
RT   transferases.";
RL   Anticancer Res. 13:1425-1430(1993).
//